Objective：This study aims to study the effect of elevated hs-cTnT on clinical outcome and mortality in AIS patients who were under intravenous thrombolytic therapy after 90 days and explore the factors affecting hs-cTnT elevation. Methods：The clinical data of 262 patients were collected and retrospectively analyzed. They were divided into hs-cTnT elevation group（n=70）and hs-cTnT normal group（n=192），poor outcome group（n=94）and good outcome group（n=168），mortality group（n=24）and survival group（n=238）. Groups comparison，univariate regression analysis，multivariate regression analysis were performed. Results：Multivariate regression analysis results showed that，factors associated with hs-cTnT elevation were elderly（OR=1.062，95%CI：1.029~1.097，P < 0.001），male patients（OR=4.35，95%CI：1.982~9.545，P < 0.001）and admission NIHSS score（OR=1.062，95%CI：1.019~1.106，P=0.004）. Factors associated with poor outcome in AIS patients who were under intravenous thrombolytic therapy after 90 d were elderly（OR=1.031，95%CI：1.003~1.059，P=0.028）and admission NIHSS score（OR=1.086，95%CI：1.042~1.131，P < 0.001）. Factors associated with mortality in AIS patients who were under intravenous thrombolytic therapy after 90 d were hs-cTnT elevation（OR=5.31，95%CI：1.025~27.517，P=0.047），admission NIHSS score（OR=1.126，95%CI：1.057~1.200，P < 0.001）and high blood pressure（OR=4.254，95%CI：1.387~13.046，P=0.011）. Conclusion：Elderly，male patients in AIS with high NIHSS scores at admission had higher levels of hs-cTnT. Thus hs-cTnT could be used as a possible marker to predict 90 d mortality after intravenous thrombolysis in AIS patients.